Table 1
Usage of secondary preventative medications in patients with acute coronary syndromes, as documented by different cardiovascular registries
| EUROASPIRE-II5 (1999–2000) (n = 8181) | GRACE15* (1999–2000) (n = 6312) | Euro Heart Survey ACS16 (2001) (n = 10484) | NRMI-317 (1999) (n = 213665) | MINAP7* (n = 156902) | ||
|---|---|---|---|---|---|---|
| (2000–1) | (2002–3) | |||||
| *The GRACE and MINAP analyses specifically excluded patients who had contraindications against these medications. | ||||||
| †The percentages for aspirin, β blockers, and ACE inhibitors have been calculated for the purpose of this analysis from data in the NRMI publication. | ||||||
| ACE, angiotensin converting enzyme; ACS, acute coronary syndromes; EUROASPIRE, European Action on Secondary and Primary Prevention Through Intervention to Reduce Events; GRACE, Global Registry of Acute Coronary Events; MINAP, Myocardial Infarction National Audit Project; NRMI, National Registry of Myocardial Infarction. | ||||||
| Aspirin (%) | 90.3 | 91 | 85.4 | 81† | 89.3 | 90.2 |
| β Blockers (%) | 66.2 | 71 | 73.8 | 65† | 76.3 | 82.6 |
| ACE inhibitors (%) | 37.6 | 55 | 56.9 | 40† | 62.4 | 72.4 |
| Statins (%) | 42.7 | 47 | 53.0 | 36.2 | 69.9 | 83.8 |
